A South Korean biotechnology company, L&C Bio, is preparing to introduce an innovative injectable treatment aimed at combating the facial volume loss commonly termed 'Ozempic face.' This condition is a side effect reported by some individuals using popular GLP-1 weight-loss medications like Ozempic, leading to hollowed cheeks and sagging skin.
MegaAdipoECM: A Novel Approach to Facial Rejuvenation
L&C Bio's new product, tentatively named MegaAdipoECM, is an injectable skin booster derived from donated human fat. Unlike traditional fillers, this treatment processes donated fat into an extracellular matrix, which serves as a scaffold. This unique mechanism encourages a patient's own fat cells to repopulate the treated areas, naturally restoring lost volume and improving skin quality.
According to CEO Lee Whan Chul, the company developed this technology approximately five years ago and holds patents in South Korea, the United States, and China. Beyond addressing 'Ozempic face,' MegaAdipoECM is also being explored as a biological alternative to silicone breast implants, highlighting its versatility in aesthetic and reconstructive applications.
Overcoming Regulatory Hurdles for Late 2027 Launch
Commercialization of MegaAdipoECM faced delays due to South Korean law, which previously classified donated fat as medical waste, prohibiting its reuse. However, lawmakers revised this legislation in 2026, legalizing the practice. This crucial regulatory change has paved the way for L&C Bio to proceed with domestic production without incurring additional raw material costs that would have arisen from manufacturing abroad.
Following a one-year grace period post-legalization, L&C Bio anticipates launching MegaAdipoECM in late 2027. The company is betting on significant demand driven by the widespread use of blockbuster weight-loss drugs.
Ethical Considerations and Future Debates
The development and commercialization of treatments utilizing donated human tissue, such as MegaAdipoECM, are likely to reignite ethical debates. Critics often argue that commercializing donated biological materials could potentially divert scarce resources from critical medical needs, such as burn victims or trauma patients. However, CEO Lee Whan Chul emphasizes that donors explicitly consent to the aesthetic use of their tissue, advocating for clearer regulations to ensure transparency and proper oversight in this evolving field.